Business
Press Release Nov 14 2022
Strides Pharma Science Limited has informed the Exchange about press release dated 14-Nov-2022 titled Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis.
About this update from Strides Pharma Science Ltd
[{"type":"text","content":" Strides Pharma Science Limited has informed the Exchange about press release dated 14-Nov-2022 titled Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis. View Attachment","length":439,"tagName":"div"}]